606-51-9 Usage
Description
(-)-Manthine, a derivative of vitamin B6, is a chemical compound with notable therapeutic properties. It has gained attention for its potential anti-inflammatory, anti-cancer, and anti-diabetic effects, making it a promising candidate for various medical applications.
Uses
Used in Pharmaceutical Industry:
(-)-Manthine is used as an anti-inflammatory agent for its ability to reduce inflammation, which can be beneficial in treating various inflammatory conditions.
(-)-Manthine is used as an anti-cancer agent for its demonstrated ability to inhibit the growth of cancer cells, offering a potential therapeutic option for cancer treatment.
(-)-Manthine is used as an anti-diabetic agent for its potential to lower blood sugar levels and improve insulin sensitivity, making it a promising option for managing diabetes.
Check Digit Verification of cas no
The CAS Registry Mumber 606-51-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,0 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 606-51:
(5*6)+(4*0)+(3*6)+(2*5)+(1*1)=59
59 % 10 = 9
So 606-51-9 is a valid CAS Registry Number.
606-51-9Relevant articles and documents
Synthetic analogues of the montanine-type alkaloids with activity against apoptosis-resistant cancer cells
Govindaraju, Karthik,Ingels, Aude,Hasan, Md Nabiul,Sun, Dandan,Mathieu, Veronique,Masi, Marco,Evidente, Antonio,Kornienko, Alexander
, p. 589 - 593 (2018/02/09)
In a search of small molecules active against apoptosis-resistant cancer cells, a skeletal rearrangement of alkaloid haemanthamine was utilized to generate a series of compounds possessing the alkaloid montanine ring system. The synthesized compounds were found to inhibit proliferation of cancer cells resistant to apoptosis at micromolar concentrations. Selected compounds were also active against patient-derived glioblastoma cells expressing stem-cell markers. This is the first report describing the preparation of synthetic analogues of the montanine-type alkaloids with antiproliferative activity. The compounds prepared in the current investigation appear to be a useful starting point for the development of agents to fight cancers with apoptosis resistance, and thus, associated with poor prognoses.
